Recent developments in biomarker guided therapy for Crohn’s disease

Despite major scientific advances, precision medicine in CD remains largely unrealized, hindered by a lack of validated and deployable biomarkers. The field must urgently pivot from discovery to implementation, embedding biomarkers into clinical trial design, validating multi-omic signatures across diverse subtypes, and overcoming real-world barriers of cost, standardization, and regulation. We can no longer accept navigating CD management blindfolded. Precision medicine should no longer be a distant aspiration. It should be the standard we hold ourselves to. The ceiling will only break when we stop accepting it.